Citations

Showing 10 of 108104 citations.

Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
Voorhees, Peter M. , Goldschmidt, Hartmut , Bandekar, Rajesh, Kuppens, Steven, Qi, Ming , Rajkumar, S. Vincent , Baker, Ross , Neff, Tobias , Dimopoulos, Meletios Α.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8062-TPS8062

10.1200/jco.2018.36.15_suppl.tps8062 Get It

Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
Risse, Marie‐Laure , Asset, Gaëlle, Martin, Thomas G. , Dimopoulos, Meletios Α. , Yong, Kwee , Mıkhael, Joseph , Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8060-TPS8060

10.1200/jco.2018.36.15_suppl.tps8060 Get It

Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).
Beksaç, Meral , Hájek, Roman , Mateos, María‐Victoria , Spencer, Andrew , Iida, Shinsuke , Farias, Danielle de, Labotka, Richard, Skácel, Tomáš, Palumbo, Antonio , Kumar, Shaji , Hajek, Roman , Chng, Wee Joo , Weisel, Katja C , Lonial, Sagar , Dimopoulos, Meletios Α.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20049-e20049

10.1200/jco.2018.36.15_suppl.e20049 Get It

Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): A SEER-Medicare analysis.
Parikh, Kejal , Clancy, Zoe, Zhou, Zheng‐Yi , Cheung, Claudia , Zhou, Zhou , Xie, Jipan , Tang, Wenxi , Ailawadhi, Sikander

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20030-e20030

10.1200/jco.2018.36.15_suppl.e20030 Get It

Trends of hospitalization for multiple myeloma patients: Insights from the national inpatient sample database.
Vakiti, Anusha , Jonnalagadda, Anil Kumar , Moustafa, Muhamad Alhaj , Stingo, Facundo E. , Mewawalla, Prerna , Moustafa, Muhamad Alhaj , Patel, Bhavisha A. , Shenoy, Aarthi

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20015-e20015

10.1200/jco.2018.36.15_suppl.e20015 Get It

Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
Cho, Daniel C. , Dowlati, Afshin , Chung, Ki Y. , Schneider, Bryan J. , Razak, Albiruni Ryan Abdul, Tsai, Frank , Balmanoukian, Ani Sarkis, Xiao, Feng , Angra, Natasha, Abdullah, Shaad E. , Mahipal, Amit , Chow, Warren , Segal, Neil Howard , Nemunaitis, John , Bazhenova, Lyudmila , Luke, Jason J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8517-8517

10.1200/jco.2018.36.15_suppl.8517 Get It

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
Szlosarek, Peter W. , Moulec, Sylvestre Le , Popat, Sanjay , Planchard, David , Scherpereel, Arnaud , Jahan, Thierry, Koczywas, Marianna , Peikert, Tobias, Campbell, Carly , Sapir, I., McDonald, Alice , Oei, Coreen, Clawson, Alicia, Roche, Maria , Popat, Sanjay , Zauderer, Marjorie G. , Taylor, Paul D. , Forster, Martin D , Cameron, Robert Bruce , Fennell, Dean Anthony

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8515-8515

10.1200/jco.2018.36.15_suppl.8515 Get It

Daratumumab-based therapies in patients with AL amyloidosis.
Abeykoon, Jithma P. , Zanwar, Saurabh , Kumar, Shaji , Lacy, Martha Q. , Kourelis, Taxiarchis , Kyle, Robert A. , Kapoor, Prashant , Dispenzieri, Angela , Rajkumar, S. Vincent , Dingli, David , Leung, Nelson , Muchtar, Eli , Gonsalves, Wilson I. , Buadi, Francis K. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8053-8053

10.1200/jco.2018.36.15_suppl.8053 Get It

Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).
Tandon, Nidhi , Lacy, Martha Q. , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Sidana, Surbhi , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8045-8045

10.1200/jco.2018.36.15_suppl.8045 Get It

Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.
Rifkin, Robert M. , Gasparetto, Cristina, Toomey, Kathleen, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Srinivasan, Shankar , YoussefAgha, Ahmed, Ung, Brian , Kitali, Amani, Flick, E. Dawn, Agarwal, Amit , Abonour, Rafat , Jagannath, Sundar , Gasparetto, Cristina , Hardin, James W. , Wagner, Lynne I. , Ailawadhi, Sikander

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8041-8041

10.1200/jco.2018.36.15_suppl.8041 Get It